Skip to main content
|

Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer

Short Title: NRG-GU015


Enrollment Status: Recruiting

NCT #: NCT07097142

Specialty Area: Oncology

Condition Studied: Muscle-Invasive Bladder Cancer

Age Groups: Adult; Older Adult

Phase: III


Study Information

Summary / Purpose

To find out if a shorter course of radiation therapy works as well as the usual radiation schedule when combined with chemotherapy for bladder cancer.

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Adults 18+ years of age
  • Diagnosed with muscle-invasive bladder cancer
  • Must be eligible to receive chemotherapy with cisplatin, gemcitabine, mitomycin, or 5-fluorouracil (5-FU)
  • Must be able to undergo radiation therapy
  • No prior pelvic radiation or treatments that would interfere with study participation

What's Involved

Participation in the study will include:
  • Treatment with either shorter duration radiation therapy (ultra-hypofractionated) OR standard radiation therapy (hypofractionated)
  • Chemotherapy with cisplatin, gemcitabine, mitomycin, or 5-fluorouracil (5-FU) given intravenously (IV)
  • CT scans, MRI, and PET scans to monitor response to treatment
  • Blood and tissue sample collection to monitor your health and treatment effects
  • Questionnaires

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.

Health & Wellness eNews
Sign Up